Lithotripsy Clinical Trials

Clinical trials related to Lithotripsy Procedure

Intravascular Lithotripsy Plus Drug-coated Balloon in Calcified Small Coronary Vessels: a Feasibility Exploratory Study

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

Drug-eluting stent (DES) implantation as interventional strategy for lesions in small coronary arteries is the current standard of care in many centers worldwide, but is associated with increased risk of late treatment failure in small vessels, as compared with larger coronary arteries. Randomized and observational studies have been shown that coronary intervention with drug-coated balloons (DCB) provide a promising alternative to DES implantation in small vessels, while avoiding the risk of a permanent vascular implant. Furthermore, lesions in small vessels are frequently concomitant with diffuse disease and/or distal location, where the presence of calcification is an additional common feature. Intravascular lithotripsy (IVL) has been recently introduced as a novel adjunctive technology to treat calcified lesions. This study will explore the hypothesis that IVL has the potential to enhance the results of coronary balloon dilatation of small vessels with calcified lesions, therefore increasing the likelihood of optimal DBC intervention.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 years or older

• Coronary artery disease with percutaneous intervention clinically indicated to treat one or more lesions fulfilling all criteria below:

‣ De novo lesion with diameter stenosis \> 50% (visual analysis)

⁃ Coronary vessel diameter \< 3.0 mm (visual analysis)

⁃ Severe calcification at the target segment, defined as fluoroscopic radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least 1 location OR Intravascular Ultrasound/Optical Coherence Tomography (IVUS/OCT) demonstrated calcium angle of ≥270° on at least 1 cross section.

• Written informed consent

Locations
Other Locations
Brazil
Hospital Israelita Albert Einstein
RECRUITING
São Paulo
Italy
University of Verona
RECRUITING
Verona
Contact Information
Primary
Annelena Held-Wehmöller, PhD
shockwave_dcb@redeoptimus.com
+4915785128140
Time Frame
Start Date: 2023-06-16
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 50
Related Therapeutic Areas
Sponsors
Leads: Rede Optimus Hospitalar SA

This content was sourced from clinicaltrials.gov